EndoQuest Robotics, a Houston, TX-based medical device company, raised $42M in C-1 funding.
The round was led by CE Ventures and McNair Interests, along with Puma Venture Capital LLC as a new investor.
The newly acquired capital will be instrumental in driving key initiatives, including further research and development, regulatory milestones, commercialization efforts, and strengthening the Company’s position as the frontrunner in flexible endoluminal robotics.
Led by CEO Kurt Azarbarzin, EndoQuest Robotics is a leader in the development of endoluminal robotic technologies. It is focused on addressing the unmet needs in gastrointestinal (“GI”) and other endoluminal surgeries by developing an innovative robotic system that offers precision, flexibility, and improved patient outcomes. The company’s proprietary technology is designed to navigate and perform procedures within the body’s luminal spaces, allowing for minimally invasive interventions and enhancing the capabilities of healthcare professionals.
EndoQuest’s Flexible Robotic System is under development, has not been cleared by the FDA and is not for commercial sale in the United States.
